Ononin mitigates streptozotocin-induced diabetic nephropathy in rats via alleviating oxidative stress and inflammatory markers

Abstract

Objective: Diabetic nephropathy (DN) is a foremost complications among diabetic patients worldwide with growing prevalence and mortality rates annually. Nearly, 25–40% of diabetic patients suffer from DN. Objective: The current research work was done to ascertain the therapeutic properties of ononin against the streptozotocin (STZ)-challenged DN in rats via alleviating oxidative stress and inflammatory responses. Methodology: The DN was initiated to experimental rats via intraperitoneal injection of 60 mg/kg of STZ. Then DN animals were supplemented orally with three various doses of ononin at 10, 25, and 50 mg/kg once a day for 60 days. After the completion, the glucose level and bodyweight of the animals were recorded. The renal function markers like creatinine, BUN, uric acid, and microalbumin (U-mAlb) was assessed using hematological analyzer. The contents of IL-6, IL-1β, TNF-α, TGF-β1, and fibronectin was assessed using assay kits. The levels of ROS and antioxidant biomarkers were assessed using standard techniques and renal tissues were examined histologically. Results: The ononin treatment substantially improved the bodyweight and depleted the FBG level, BUN, creatinine, uric acid, and U-mAlb levels in the STZ-challenged DN animals. The levels of inflammatory and fibrosis factors i.e. IL-6, IL-1β, TNF-α, TGF-β1, and fibronectin was remarkably depleted by the ononin treatment. The ononin also decreased the ROS level and improved the GSH content, SOD and GPx activities in the STZ-challenged DN animals. The findings of histological study also confirmed the therapeutic roles of ononin against STZ-induced changes in renal tissues. Conclusion: Altogether, our results from this study evidences the beneficial roles of ononin treatment against the STZ-initiated DN in animals via its antioxidant and anti-inflammatory properties. Hence, it could be the potential candidate in the future for the management of DN.

Keywords

• Diabetic nephropathy
• Ononin
• N-acetyl-β-D-glucosaminidase
• ROS
• Inflammation